Gilead Sciences clinical trial pipeline

17 trials changed in the last 30 days: 0 stopped, 8 with notable changes, 9 with minor changes only.

1. Notable

   ARTISTRY-1 · Bictegravir/Lenacapavir Versus Current Therapy…ARTISTRY-1 · Bictegravir/Lenacapavir Versus Current Therapy · HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

   Results posted: Oct 21, 2026

   Also in this update: Primary endpoint(s) modified; Study completion pushed from Jul 2028 to Dec 2029

   Gilead Sciences·Phase 2/3· NCT05502341· Registry history of NCT05502341 on ClinicalTrials.gov (opens the registry)

   Oct 21, 2026

2. Notable

   Anitocabtagene Autoleucel · Non-Oncology Plasma Cell-Related…Anitocabtagene Autoleucel · Non-Oncology Plasma Cell-Related Diseases

   Primary and study completion dates pushed to Oct 2028

   Also in this update: Primary endpoint(s) modified; Sponsor changed: Arcellx, Inc. to Kite, A Gilead Company

   Kite, A Gilead Company·Phase 1· NCT06626919· Registry history of NCT06626919 on ClinicalTrials.gov (opens the registry)

   Oct 22, 2026

3. Notable

   HERMOSA-2 · KITE-363 · Autoimmune Neurologic Diseases That Did…HERMOSA-2 · KITE-363 · Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment

   Primary endpoint(s) modified

   Also in this update: Trial arms changed: 2 → 3

   Kite, A Gilead Company·Phase 1· NCT07304154· Registry history of NCT07304154 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

4. Notable

   Cell Therapies · Relapsed or Refractory Acute Myeloid Leukemia or…Cell Therapies · Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

   Sponsor changed: Arcellx, Inc. to Kite, A Gilead Company

   Also in this update: Primary endpoint(s) modified; Interventions modified

   Kite, A Gilead Company·Phase 1· NCT05457010· Registry history of NCT05457010 on ClinicalTrials.gov (opens the registry)

   Oct 2, 2026

5. Notable

   Bictegravir/Lenacapavir in Children and · HIV-1

   Primary completion pushed from Nov 2026 to Jul 2030

   And 2 more changes in the last 30 days

   Gilead Sciences·Phase 2/3· NCT06532656· Registry history of NCT06532656 on ClinicalTrials.gov (opens the registry)

   Sep 29, 2026

6. Notable

   KITE-363 · Refractory Autoimmune Diseases

   Primary and study completion pushed from Jul 2029 to Sep 2030

   Kite, A Gilead Company·Phase 1· NCT07038447· Registry history of NCT07038447 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

7. Notable

   Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by…Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth · HIV-1 With Undetectable Virus Levels

   Recruitment opened

   Also in this update: Start date changed from estimate of Sep 2026 to Oct 1, 2026

   Gilead Sciences·Phase 2· NCT07841990· Registry history of NCT07841990 on ClinicalTrials.gov (opens the registry)

   Oct 23, 2026

8. Notable

   Provide Continued Access to Study Drug to Children and Adolescents…Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

   Primary completion moved earlier from Mar 2034 to Jun 2027

   Gilead Sciences·Phase 4· NCT06337032· Registry history of NCT06337032 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.